Results 31 to 40 of about 8,688 (186)

Clinical periodontal diagnosis

Periodontology 2000, EarlyView., 2023
Abstract Periodontal diseases include pathological conditions elicited by the presence of bacterial biofilms leading to a host response. In the diagnostic process, clinical signs such as bleeding on probing, development of periodontal pockets and gingival recessions, furcation involvement and presence of radiographic bone loss should be assessed prior ...
Giovanni E. Salvi, Andrea Roccuzzo, Jean‐Claude Imber, Alexandra Stähli, Björn Klinge, Niklaus P. Lang   +5 more
wiley   +1 more source

Regression of cutaneous squamous cell carcinoma after the development of pembrolizumab‐induced bullous pemphigoid

JEADV Clinical Practice, 2023
Bullous pemphigoid is a rare complication of immune checkpoint inhibitor treatment. We report a case of pembrolizumab‐induced bullous pemphigoid in a patient with malignant melanoma and concomitant cutaneous squamous cell carcinoma that regressed.
Shin Iinuma, Kei Hayashi, Akemi Ishida‐Yamamoto   +2 more
doaj   +1 more source

Bullous Pemphygoid and Novel Therapeutic Approaches

Biomedicines, 2022
Bullous pemphigoid is a subepidermal blistering disease associated with autoantibodies (auto-ab) to BP180 and BP230 which affects elderly patients, predominately.
Giovanni Marco D’Agostino, Giulio Rizzetto, Andrea Marani, Samuele Marasca, Matteo Candelora, Daisy Gambini, Helena Gioacchini, Edoardo De Simoni, Andrea Maurizi, Anna Campanati, Annamaria Offidani   +10 more
doaj   +1 more source

Bullous Pemphigoid Associated with Anti-programmed Cell Death Protein 1 and Anti-programmed Cell Death Ligand 1 Therapy: A Review of the Literature

Acta Dermato-Venereologica, 2021
Bullous pemphigoid constitutes a rare dermatological immune-related adverse event of programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors.
Aikaterini Tsiogka, Johann W. Bauer, Aikaterini Patsatsi   +2 more
doaj   +1 more source

Correlation between bullous pemphigoid and type 2 inflammation

Pifu-xingbing zhenliaoxue zazhi, 2022
Bullous pemphigoid (BP) is one of the common autoimmune blister diseases that mainly affects the elderly. Most bullous pemphigoid patients have obvious symptom of pruritus, accompanied by elevated levels of serum total IgE, peripheral blood eosinophils ...
Yao ZHOU, Guomin LI, Zhijun XU, Jie XU, Jinjin ZHENG, Hao FANG, Ruzeng XUE   +6 more
doaj   +1 more source

A Systematic Review of Drug-Induced Pemphigoid

Acta Dermato-Venereologica, 2020
Bullous pemphigoid is an autoimmune subepithelial disease characterised by pruritus followed by urticarial plaques and finally bullae on the skin and mucosa.
Matthew J. Verheyden, Asli Bilgic, Dédée F. Murrell   +2 more
doaj   +1 more source

Clinical Relevance of Autoantibodies in Patients with Autoimmune Bullous Dermatosis

Clinical and Developmental Immunology, 2012
The authors present their experience related to the diagnosis, treatment, and followup of 431 patients with bullous pemphigoid, 14 patients with juvenile bullous pemphigoid, and 273 patients with pemphigus.
Lilla Mihályi, Mária Kiss, Attila Dobozy, Lajos Kemény, Sándor Husz   +4 more
doaj   +1 more source

Pemphigoid gestationis and intravenous immunoglobulin therapy

International Journal of Women's Dermatology, 2018
Pemphigoid gestationis, which is also known as herpes gestationis, is a rare, pregnancy-associated, autoimmune bullous disease. Treatment depends on the severity of the disease for each patient and the safety and use of these drugs during pregnancy and ...
Anes Yang, MD, BMed, MPH, Elizabeth Uhlenhake, MD, FAAD, Dedee F. Murrell, MA, BMBCh, FAAD, MD, FACD, FRCP   +2 more
doaj   +1 more source

Lower Extremity Salvage in the Setting of Bullous Pemphigoid Exacerbation: A Case Report

Plastic and Reconstructive Surgery, Global Open, 2021
Summary:. Bullous pemphigoid is an autoimmune blistering disease where patients suffer from painful bullae, often covering large portions of the skin and requiring management with immune-suppression.
Samara E. Pollock, MD, Shauna M. Rice, BS, Sarah D. Ferree, MD, Jonathan Friedstat, MD, MPH, Kyle Eberlin, MD, Arianne S Kourosh, MD MPH   +5 more
doaj   +1 more source

Dupilumab Beyond the Airway: Decreased Morbidity in a Real‐World Analysis

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Post hoc analyses of clinical trials have characterized dupilumab's adverse effects, yet the real‐world impact in chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma is not well described. This study aims to characterize the risks of lymphoma, cardiovascular events, eosinophilia, joint pain, inflammatory arthritis, and ...
Emma J. Anisman, Spencer Short, Emma Tam, Benjamin F. Bitner, Abdulghafoor Alani, Marc Rosen, Mindy Rabinowitz, Damaris Pena Evertz, Elina Toskala, Gurston G. Nyquist   +9 more
wiley   +1 more source